MEOBF
Price
$1.35
Change
-$0.00 (-0.00%)
Updated
Nov 11 closing price
Capitalization
1.91B
7 days until earnings call
Intraday BUY SELL Signals
SPHDF
Price
$13.35
Change
+$1.08 (+8.80%)
Updated
Nov 13 closing price
Capitalization
173.21M
Intraday BUY SELL Signals
Interact to see
Advertisement

MEOBF vs SPHDF

Header iconMEOBF vs SPHDF Comparison
Open Charts MEOBF vs SPHDFBanner chart's image
Mesoblast
Price$1.35
Change-$0.00 (-0.00%)
Volume$1.09K
Capitalization1.91B
Santhera Pharmaceuticals Holdings
Price$13.35
Change+$1.08 (+8.80%)
Volume$200
Capitalization173.21M
MEOBF vs SPHDF Comparison Chart in %
MEOBF
Daily Signal:
Gain/Loss:
SPHDF
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
MEOBF vs. SPHDF commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MEOBF is a Hold and SPHDF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (MEOBF: $1.35 vs. SPHDF: $13.35)
Brand notoriety: MEOBF and SPHDF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MEOBF: 43% vs. SPHDF: 42%
Market capitalization -- MEOBF: $1.88B vs. SPHDF: $180.63M
MEOBF [@Biotechnology] is valued at $1.88B. SPHDF’s [@Biotechnology] market capitalization is $180.63M. The market cap for tickers in the [@Biotechnology] industry ranges from $106.82B to $0. The average market capitalization across the [@Biotechnology] industry is $2.15B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MEOBF’s FA Score shows that 0 FA rating(s) are green whileSPHDF’s FA Score has 1 green FA rating(s).

  • MEOBF’s FA Score: 0 green, 5 red.
  • SPHDF’s FA Score: 1 green, 4 red.
According to our system of comparison, SPHDF is a better buy in the long-term than MEOBF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MEOBF’s TA Score shows that 3 TA indicator(s) are bullish while SPHDF’s TA Score has 3 bullish TA indicator(s).

  • MEOBF’s TA Score: 3 bullish, 4 bearish.
  • SPHDF’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, SPHDF is a better buy in the short-term than MEOBF.

Price Growth

MEOBF (@Biotechnology) experienced а 0.00% price change this week, while SPHDF (@Biotechnology) price change was +8.76% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.17%. For the same industry, the average monthly price growth was -5.68%, and the average quarterly price growth was +64.91%.

Reported Earning Dates

MEOBF is expected to report earnings on Nov 26, 2025.

Industries' Descriptions

@Biotechnology (-2.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MEOBF($1.91B) has a higher market cap than SPHDF($173M). SPHDF YTD gains are higher at: 41.720 vs. MEOBF (-38.636).
MEOBFSPHDFMEOBF / SPHDF
Capitalization1.91B173M1,105%
EBITDA-73.66MN/A-
Gain YTD-38.63641.720-93%
P/E RatioN/A2.53-
Revenue17.2MN/A-
Total Cash161MN/A-
Total Debt128MN/A-
FUNDAMENTALS RATINGS
MEOBF vs SPHDF: Fundamental Ratings
MEOBF
SPHDF
OUTLOOK RATING
1..100
3443
VALUATION
overvalued / fair valued / undervalued
1..100
84
Overvalued
55
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
93100
PRICE GROWTH RATING
1..100
6061
P/E GROWTH RATING
1..100
449
SEASONALITY SCORE
1..100
23n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SPHDF's Valuation (55) in the null industry is in the same range as MEOBF (84). This means that SPHDF’s stock grew similarly to MEOBF’s over the last 12 months.

SPHDF's Profit vs Risk Rating (100) in the null industry is in the same range as MEOBF (100). This means that SPHDF’s stock grew similarly to MEOBF’s over the last 12 months.

MEOBF's SMR Rating (93) in the null industry is in the same range as SPHDF (100). This means that MEOBF’s stock grew similarly to SPHDF’s over the last 12 months.

MEOBF's Price Growth Rating (60) in the null industry is in the same range as SPHDF (61). This means that MEOBF’s stock grew similarly to SPHDF’s over the last 12 months.

SPHDF's P/E Growth Rating (9) in the null industry is somewhat better than the same rating for MEOBF (44). This means that SPHDF’s stock grew somewhat faster than MEOBF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MEOBFSPHDF
RSI
ODDS (%)
Bearish Trend 2 days ago
53%
Bullish Trend 2 days ago
64%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
52%
Bearish Trend 2 days ago
50%
Momentum
ODDS (%)
Bullish Trend 2 days ago
49%
Bullish Trend 2 days ago
42%
MACD
ODDS (%)
Bearish Trend 2 days ago
56%
Bullish Trend 2 days ago
29%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
51%
Bullish Trend 2 days ago
12%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
49%
Bullish Trend 2 days ago
13%
Advances
ODDS (%)
Bullish Trend 27 days ago
50%
N/A
Declines
ODDS (%)
N/A
N/A
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
58%
View a ticker or compare two or three
Interact to see
Advertisement
MEOBF
Daily Signal:
Gain/Loss:
SPHDF
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PQUAX12.29N/A
N/A
PACE Small/Medium Co Growth Equity A
FGIWX13.25N/A
N/A
Nuveen Global Infrastructure R6
DFVEX29.32-0.08
-0.27%
DFA US Vector Equity I
VCRIX14.70-0.10
-0.68%
NYLI CBRE Global Infrastructure Class I
REDWX18.95-0.21
-1.10%
GreenFi Redwood Fund

MEOBF and

Correlation & Price change

A.I.dvisor indicates that over the last year, MEOBF has been loosely correlated with SPHDF. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if MEOBF jumps, then SPHDF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MEOBF
1D Price
Change %
MEOBF100%
N/A
SPHDF - MEOBF
50%
Loosely correlated
N/A
AVTX - MEOBF
46%
Loosely correlated
+6.67%
COGT - MEOBF
39%
Loosely correlated
-1.08%
MESO - MEOBF
26%
Poorly correlated
-1.59%
KROS - MEOBF
26%
Poorly correlated
+0.98%
More

SPHDF and

Correlation & Price change

A.I.dvisor indicates that over the last year, SPHDF has been loosely correlated with COGT. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if SPHDF jumps, then COGT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPHDF
1D Price
Change %
SPHDF100%
N/A
COGT - SPHDF
63%
Loosely correlated
-1.08%
MEOBF - SPHDF
50%
Loosely correlated
N/A
KROS - SPHDF
38%
Loosely correlated
+0.98%
CYTOF - SPHDF
35%
Loosely correlated
-2.17%
XFOR - SPHDF
34%
Loosely correlated
-1.37%
More